Back

A meta analysis of effects of high-intensity statin and pcsk-9 inhibitor therapies on coronary plaque burden

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Multimodality imaging of coronary artery disease Imaging of Coronary Artery Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Erdin Tokmak

University of Duisburg-Essen - West-German Heart and Vascular Centre, Essen (Germany)

7 More presentations in this session

Presentation thumbnail
Lipid core burden index and new LDL-C calculation in predicting non-culprit coronary events in very high-risk patients: Insights from the Lipid-Rich Plaque Study
Associate Professor J. Wykrzykowska (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Relationship between lipoprotein(a) and pancoronary plaque vulnerability in patients with acute coronary syndrome: a three-vessel optical coherence tomography study
Doctor C. Fang (Harbin, CN)
Abstract Slides Video
Presentation thumbnail
Long-term prognostic value of residual lipid burden in acute myocardial infarction: a three-vessel optical coherence tomography study
Doctor L. Cui (Harbin, CN)
Abstract Slides Video
Presentation thumbnail
Impact of modified vs. non-compliant balloons on tissue modifications in severely calcified lesions following atherectomy: a DIRO sub-study
Doctor S. Kawanami (Sakai, JP)
Abstract Slides Video
Presentation thumbnail
IVUS findings predicting the indication for intravascular lithotripsy in PCI
Doctor K. Hattori (Yokohama, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Multimodality imaging of coronary artery disease

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Impact of intensive low-density lipoprotein cholesterol lowering therapy on intermediate stenosis in non-culprit vessels of acute coronary syndrome
thumbnail
Congress Session
Changing face of lipid-lowering therapy
thumbnail
Congress Session
Refining efficacy and safety of lipid-lowering pharmacotherapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources